Exploring human CYP4 enzymes: Physiological roles, function in diseases and focus on inhibitors

Drug Discov Today. 2023 May;28(5):103560. doi: 10.1016/j.drudis.2023.103560.

Manzhen Zhou ¹, Junda Li ¹, Jinyi Xu ¹, Lufeng Zheng ², Shengtao Xu ³

Affiliations

1 Department of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.
2 School of Life Science and Technology, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.
3 Department of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China; Department of Hepatobiliary Surgery, The First People's Hospital of Kunshan, Suzhou 215300, China. Electronic address: [email protected].

PMID: 36958639 DOI: 10.1016/j.drudis.2023.103560

Abstract

The Cytochrome P450 (CYP)4 family of Enzymes are monooxygenases responsible for the ω-oxidation of endogenous fatty acids and eicosanoids and play a crucial part in regulating numerous eicosanoid signaling pathways. Recently, CYP4 gained attention as a potential therapeutic target for several human diseases, including Cancer, cardiovascular diseases and inflammation. Small-molecule inhibitors of CYP4 could provide promising treatments for these diseases. The aim of the present review is to highlight the advances in the field of CYP4, discussing the physiology and pathology of the CYP4 family and compiling CYP4 inhibitors into groups based on their chemical classes to provide clues for the future discovery of drug candidates targeting CYP4.

Keywords

CYP4; CYP4 inhibitors; CYP450; endogenous fatty acid; ω-hydroxylation.

Name
Email *

	Sorry, but the email address you supplied was invalid.